Results 11 to 20 of about 8,807 (99)

Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4 [PDF]

Human Vaccines & Immunotherapeutics
Nectin-4 has emerged as a pivotal therapeutic target for antibody-drug conjugates (ADCs), particularly in advanced urothelial carcinoma (aUC) research. Although extensive literature has been reported on Nectin-4, it is worth noting that no studies have ...
Yu Qiao, Wanyu Zhao, Yusen Gou, Yuwei Li, Fang Su, Rui Wang, Jiejun Wang, Haibo Zhang, Lei Sun, Feng Qian, Zishu Wang   +10 more
doaj   +2 more sources

Therapeutic prospects of nectin-4 in cancer: applications and value [PDF]

Frontiers in Oncology
Nectin-4 is a Ca2+-independent immunoglobulin-like protein that exhibits significantly elevated expression in malignant tumors while maintaining extremely low levels in healthy adult tissues.
Kaiyue Li, Yujing Zhou, Maolin Zang, Xin Jin, Xin Li   +4 more
doaj   +2 more sources

Expression patterns of TROP2 and Nectin-4 in oropharyngeal squamous cell carcinoma in relation to HPV status: potential biomarkers for targeted therapy [PDF]

Therapeutic Advances in Medical Oncology
Background: Patients with inoperable or metastatic oropharyngeal squamous cell carcinoma (OSCC) face limited therapeutic options. Nectin-4, an immunoglobulin-like transmembrane adhesion protein, and Trophoblast Surface Antigen 2 (TROP2), a transmembrane ...
Charlotte Klasen, Hans N. C. Eckel, Nora Wuerdemann, Joseph Böckelmann, Karl Knipper, Malte Suchan, Kariem Sharaf, Shachi Jenny Sharma, Helen Abing, Arthur Charpentier, Julia Esser, Kevin Hansen, Marcel Mayer, Louis Jansen, Jens Peter Klußmann, Alexander Quaas, Su Ir Lyu   +16 more
doaj   +2 more sources

Deficient DNA mismatch repair and Nectin-4 expression in upper tract urothelial carcinoma (UTUC) [PDF]

Journal of Cancer Research and Clinical Oncology
Purpose To investigate the prevalence of deficient DNA mismatch repair (dMMR) status in upper tract urothelial carcinoma (UTUC) and its association with clinicopathological characteristics as well as Nectin-4 immunohistochemical expression.
Peichen Duan, Le Yu, Yichang Hao, Shaohui Deng, Peng Hong, Min Lu, Shudong Zhang   +6 more
doaj   +2 more sources

Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression in endometrial carcinosarcoma [PDF]

Gynecologic Oncology Reports
Objective: To characterize the immunohistochemical expression of human epidermal growth factor receptor-2 (HER2), nectin-4, and trophoblast cell surface antigen-2 (TROP2) in endometrial carcinosarcoma (ECS), with particular attention to compartment ...
Shih-Yao Lin, Chung-Ting Chang, Ren-Chin Wu, Chiung-Ru Lai, Yi-Jen Chen   +4 more
doaj   +2 more sources

A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE [PDF]

Cell Death and Disease
Research and development on Nectin-4 antibody-drug conjugates (ADC) have been greatly accelerated since the approval of enfortumab vedotin to treat uroepithelial cancer.
Yichen Wang, Yanyang Nan, Chunguang Ma, Xiaolin Lu, Qian Wang, Xiting Huang, Wenjing Xue, Jiajun Fan, Dianwen Ju, Dingwei Ye, Xuyao Zhang   +10 more
doaj   +2 more sources

Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs [PDF]

BMC Cancer
Upper tract urothelial carcinoma (UTUC) and urinary bladder cancer (UBC), though histologically similar, differ molecularly, prompting interest in their biomarker profiles for targeted therapies like antibody-drug conjugates (ADCs) enfortumab vedotin ...
Mohammed Rafea Kanaan, Jessica Schmitz, Jan Hinrich Braesen, Markus Antonius Kuczyk, Hossein Tezval   +4 more
doaj   +2 more sources

Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss [PDF]

IJU Case Reports
Introduction Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin‐4 expression.
Takahito Wakamiya, Yuya Iwahashi, Hiroki Kawabata, Satoshi Muraoka, Shimpei Yamashita, Fumiyoshi Kojima, Yasuo Kohjimoto   +6 more
doaj   +2 more sources

Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4–targeting PET tracer [⁶⁸Ga]Ga-FZ-NR-1 in humans [PDF]

EJNMMI Research
Background Nectin-4 is a promising theranostic target for cancers treatment due to its high abundance/expression in different cancer entities such as bladder cancer, breast cancer, and pancreatic cancer This study evaluated the biodistribution and ...
Xiaoqiang Shi, Hongxing Yang, Ming Qi, Wen Chen, Haoyao Guo, Meng Xiao, Chunjuan Jiang, Ni Zhang, Zhihao Chen, Xiaoping Xu, Shaoli Song, Jianping Zhang   +11 more
doaj   +2 more sources

Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers [PDF]

Journal for ImmunoTherapy of Cancer
Background T-cell costimulation is crucial for an effective and sustained antitumor immune response, and inadequate expression of costimulatory ligands within tumors can impair T-cell function.
Manpreet Kaur, Starlynn C Clarke, Katherine E Harris, Nathan D Trinklein, Elaine C Chen, Katja Rüger, Udaya S Rangaswamy, Laura M Davison, Sebastian Moreno Arteaga, Imani Smith, Ruth Chu, Soumili Chattopadhyay, Mathias Rickert, Shelley Force Aldred   +13 more
doaj   +2 more sources